Endo International ROE 2024

Endo International Aktienanalyse

What does Endo International do?

Endo International PLC is a global pharmaceutical company based in Ireland, specializing in the development, manufacturing, and distribution of prescription medications. The company was founded in New York City in 1920 as a small narcotic business and has since undergone significant changes and expansion through mergers and acquisitions. Endo now has its headquarters in Dublin, Ireland and a diverse portfolio of prescription drugs in various therapeutic areas. The company's business model focuses on the development and marketing of innovative and generic pharmaceuticals, medical devices, and diagnostic solutions to improve global patient health. It operates in five segments: Branded Pharmaceuticals, Generics, International Pharmaceuticals, Urology, and Specialty Products. The Branded Pharmaceuticals segment includes a wide range of prescription drugs targeting various indications, including pain relievers, hormone therapies, gastrointestinal products, and oncology treatments. Some of Endo's well-known brands include Lidoderm, Voltaren, and Percocet. The Generics division produces and distributes a variety of generic medications under different brand names, utilizing synergies within its network to reduce manufacturing costs and pass savings on to customers. The International Pharmaceuticals unit is responsible for Endo's global business, maintaining partnerships and joint ventures with partners worldwide and expanding the company's portfolio into new regions and markets. The Urology segment offers a broad spectrum of products and services for urology, including surgical and non-surgical procedures. This includes the globally top-selling transurethral resection generator, the GreenLight Laser. Endo's Specialty Products segment manufactures devices and active ingredients for critical infrastructure used in medical research and development. This unit has heavily focused on developing innovative solutions for medical challenges in recent years. Overall, Endo holds approximately 1% market share of the global pharmaceutical market. To strengthen its competitive position, the company focuses on expanding its product portfolio, increasing efficiency, and reducing costs. Endo has a strong presence in the American and European markets and is also active in emerging economies. It follows a growth strategy that emphasizes the introduction of new and innovative products to further expand its existing segments and explore new business areas. In 2020, Endo employed over 3500 employees worldwide and generated approximately $2.5 billion in revenue. The company aims to solidify its position as a leading pharmaceutical company and expand its influence in the global market. Endo International ist eines der beliebtesten Unternehmen auf Eulerpool.com.

ROE Details

Decoding Endo International's Return on Equity (ROE)

Endo International's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.

Year-to-Year Comparison

Analyzing Endo International's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.

Impact on Investments

Endo International's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.

Interpreting ROE Fluctuations

Changes in Endo International’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.

Frequently Asked Questions about Endo International stock

What is the ROE (Return on Equity) of Endo International this year?

The ROE of Endo International this year is 0.37 undefined.

How has the Return on Equity (ROE) of Endo International developed compared to the previous year?

The ROE of Endo International has increased by -47.13% decreased compared to the previous year.

What impact does a high ROE (Return on Equity) have on investors of Endo International?

A high ROE indicates that Endo International generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.

What impact does a low ROE (Return on Equity) have on investors of Endo International?

A low ROE can indicate that Endo International is having difficulties monetizing its investments successfully and can be a negative signal for investors.

How does a change in the ROE (Return on Equity) of Endo International affect the company?

A change in ROE (Return on Equity) of Endo International can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.

How to calculate the ROE (Return on Equity) of Endo International?

The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.

Which factors influence the ROE (Return on Equity) of Endo International?

Some factors that can influence Endo International's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.

What strategic measures can take to improve the ROE (Return on Equity)?

To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.

How much dividend does Endo International pay?

Over the past 12 months, Endo International paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Endo International is expected to pay a dividend of 0 USD.

What is the dividend yield of Endo International?

The current dividend yield of Endo International is .

When does Endo International pay dividends?

Endo International pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Endo International?

Endo International paid dividends every year for the past 0 years.

What is the dividend of Endo International?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Endo International located?

Endo International is assigned to the 'Health' sector.

Wann musste ich die Aktien von Endo International kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Endo International from 10/1/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/1/2024.

When did Endo International pay the last dividend?

The last dividend was paid out on 10/1/2024.

What was the dividend of Endo International in the year 2023?

In the year 2023, Endo International distributed 0 USD as dividends.

In which currency does Endo International pay out the dividend?

The dividends of Endo International are distributed in USD.